Previous Close | 8.31 |
Open | 8.40 |
Bid | 8.39 x 1800 |
Ask | 8.49 x 3100 |
Day's Range | 8.19 - 8.52 |
52 Week Range | 7.23 - 11.55 |
Volume | |
Avg. Volume | 9,047,208 |
Market Cap | 9.342B |
Beta (5Y Monthly) | 1.22 |
PE Ratio (TTM) | 12.83 |
EPS (TTM) | 0.66 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 27, 2017 |
1y Target Est | 11.36 |
Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said on Wednesday. The agreement is the largest state-negotiated settlement in West Virginia history, and consists of $134 million in cash plus the contribution of drugs used to treat opioid overdoses, Morrisey said at a news conference.
(Reuters) -Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday. The agreement is the largest state-negotiated settlement in West Virginia history, and consists of $134 million in cash plus the contribution of drugs used to treat opioid overdoses, Morrisey said. "This is a great day for West Virginia," Morrisey said at a press conference.
TEL AVIV, Israel & PARSIPPANY, N.J., May 25, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of West Virginia that settles the state’s and its subdivisions opioid-related claims. The settlement will provide West Virginia with $75 million over 15 years in addition to $8 million in attorneys’ fees and costs incurred during the trial. Teva will also provide its life-savin